TCI Wealth Advisors’s Theravance Biopharma TBPH Stock Holding History

TCI Wealth Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-515	Closed	-$5.59K	–	2013
2023 Q1	$5.59K	Hold	515	–	–	﹤0.01%	1450
2022 Q4	$5.78K	Hold	515	–	–	﹤0.01%	1426
2022 Q3	$5K	Hold	515	–	–	﹤0.01%	1521
2022 Q2	$5K	Hold	515	–	–	﹤0.01%	1538
2022 Q1	$5K	Hold	515	–	–	﹤0.01%	1598
2021 Q4	$6K	Buy	+515	New	+$4.49K	﹤0.01%	1576
2021 Q2	–	Sell	-92	Closed	-$2K	–	2452
2021 Q1	$2K	Buy	+92	New	+$1.75K	﹤0.01%	1902
2018 Q4	–	Sell	-7	Closed	–	–	1644
2018 Q3	$0	Sell	7 -13	-65%	-$354	﹤0.01%	1576
2018 Q2	$0	Buy	+20	New	+$475	﹤0.01%	1595

Other funds holding TBPH

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's TBPH Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Theravance Biopharma (TBPH) in Q2 2023, closing a stake of 515 shares — an estimated $5.59K sold.

TCI Wealth Advisors first reported a position in TBPH in Q2 2018 and held it in 9 quarters. The position peaked at $6K in Q4 2021. 119 funds tracked by Wall St. Rank hold TBPH as of Q2 2023.

TCI Wealth Advisors reported no remaining Theravance Biopharma position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 515 Theravance Biopharma shares in Q2 2023, an estimated $5.59K.
TCI Wealth Advisors first reported a position in Theravance Biopharma in Q2 2018 and held it in 9 quarters.
TCI Wealth Advisors's Theravance Biopharma position peaked at $6K in Q4 2021.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.